SalioGen Therapeutics is moving quickly. Ten months after exiting stealth with $20 million in series A funds, the Massachusetts-based biotech has raised another $115 million to fund its vision of the future of genetic medicines.
Novo Holdings and experienced venture capitalists on both sides of the Atlantic have come together to create a new fund focused on rare diseases. Led by VCs who spent years at Lundbeckfonden Ventures and NEA, Sound Bioventures will use its initial €110 million ($124 million) to back biotechs that are either in or on the cusp of the clinic.
A recent market research report estimated that between 2021 and 2026, the market for virtual reality in healthcare will grow by nearly 35% annually, swelling the market to more than $40 billion.
The Nordic life sciences scene is getting an injection of cash. Led by centers such as the Karolinska Institutet and Copenhagen University, the region leads the way in research in the EU by many metrics but has traditionally lacked the vibrant VC scene needed to build large numbers of biotechs. Eir Ventures wants to help change that.
A Canadian startup aims to give the decades-old, hand-performed ELISA test a 21st century upgrade by transforming the humble immunoassay into a high-throughput protein profiling platform. Formerly known as nplex biosciences, Nomic said it has worked with a small number of biopharma partners since its debut in 2018 and is looking to expand.